Predicting effective drug concentrations for individual patients: Determinants of pharmacodynamic variability

Clinical Pharmacokinetics

Volumn 34, Issue 4, 1998, Pages 323-333

  Levy, Gerhard ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; INDIVIDUALITY; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW;

ANALYSIS OF VARIANCE; CLINICAL TRIALS; DRUG THERAPY; HUMANS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 0031955702     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199834040-00005     Document Type: Review

References (36)

1. Knott C, Reynolds F. Therapeutic drug monitoring in pregnancy: rationale and current status. Clin Pharmacokinet 1990; 19: 425-33
2. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmaco-kinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71
3. Lemmens HJM, Dyck JB, Shafer SL, et al. Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther 1994; 56: 261-71
4. Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucur-onide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47-54
5. Warfield CA, Kahn CH. Acute pain management: programs in US hospitals and experiences and attitudes among US adults. Anesthesiology 1995; 83: 1090-4
6. Breitbart W, Rosenfeld BD, Passik SD, et al. The undertreatment of pain in ambulatory AIDs patients. Pain 1996; 65: 243-9
7. Fiset P, Lemmens HLM, Egan TE, et al. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. Clin Pharmacol Ther 1995; 58: 567-82
8. Koopmans R, Oosterhuis B, Karemaker JM, et al. Pharmacokinetic pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring. Eur J Clin Pharmacol 1998; 34: 395-400
9. Adam HK, Kay B, Douglas EJ. Blood disoprofol levels in anaesthetized patients. Anaesth 1982; 37: 536-40
10. Padrini R, Piovan D, Busa M, et al. Pharmacodynamic variability of flecainide assessed by QRS changes. Clin Pharmacol Ther 1993; 53: 59-64
11. 1-adrenoceptor mediated cardiovascular effects of xamoterol in healthy volunteers at rest. 3rd Symposium on Frontiers of Pharmacokinetics and Pharmacodynamics; 1990; Baltimore
12. Alradi AO, Carruthers SG. Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther 1985; 38: 495-502
13. Wald JA, Salazar DE, Cheng H, et al. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J Pharmacokinet Biopharm 1991; 19: 521-36
14. Levy G, Ebling WF, Forrest A. Concentration-or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther 1994; 56: 1-8
15. Reid JL. Dose-plasma concentration-effect relationship of felodipine in essential hypertension: a review. J Cardiovasc Pharmacol 1990; 15 (4 Suppl.): S50-6
16. Levy G. Variability in animal and human pharmacodynamic studies. In: Rowland M, Sheiner LB, Steimer J-L, editors. Variability in drug therapy: description, estimation, and control. New York: Raven Press, 1985: 125-38
17. Mandema JW, Stanski DR. Population pharmacodynamic model tor ketorolac analgesia. Clin Pharmacol Ther 1996; 60: 619-35
18. Lapka R, Sechser T, Rejholec V, et al. Pharmacokinetics and pharmacodynamics of conventional and controlled release formulations of metipranolol in man. Eur J Clin Pharmacol 1990; 38: 243-7
19. Pitsiu M, Parker EM, Aarons L, et al. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults. Eur J Pharm Sci 1993 1: 151-7
20. Egan TD, Minto CF, Hermann DJ, et al. Remifentanyl versus alfentanil. Comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 1996; 84: 821-33
21. Adkison KDK, Powers KM, Artru AA, et al. Effect of paraaminohippurate on the efflux of valproic acid from the central nervous system of the rabbit. Epilepsy Res 1996; 23: 95-104
22. Naora K, Ichikawa N, Nishimura N, et al. Saturable transport of valproic acid in rat choroid plexus in vitro. J Pharm Sci 1996; 85: 423-6
23. Nutt DJ, Woodward WR, Hammerstad JP. Pharmacokinetics of intravenous levodopa: implications for mechanisms of therapeutic actions of levodopa and carbidopa. In: Fahan S, et al., editors. Recent development in Parkinson's disease. New York: Raven Press, 1986: 239-45
24. Montgomery EB. Pharmacokinetics and pharmacodynamics of levodopa. Neurology 1992; 42 Suppl. 1: 17-22
25. Friedman A, Kaufer D, Shemer J, et al. Tur-Kaspa: pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nat Med 1996; 2: 1382-5
26. Tamsen A, Sakurada T, Wahlström A, et al. Postoperative demand for analgesics in relation to individual levels of endorphins and substance P in cerebrospinal fluid. Pain 1982; 13: 171-83
27. Dundee JW, Richards RK. Effect of azotemia upon the action of intravenous barbiturate anesthesia. Anesthesiology 1954; 15: 333-46
28. Danhof M, Hisaoka M, Levy G. Kinetics of drug action in disease states. II: effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflex. J Pharmacol Exp Ther 1984; 230: 627-31
29. Hisaoka M, Levy G. Kinetics of drug action in disease states. XIII: effect of dialyzable component(s) of uremic blood on phenobarbital concentrations in rats at onset of loss of righting reflex. J Pharmacol Exp Ther 1985; 234: 180-3
30. Whitfield LR, Levy G. Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences. Clin Pharmacol Ther 1980; 28: 509-615
31. Whitfield LR, Schentag JJ, Levy G. Relationship between concentration and anticoagulant effect of heparin in plasma of hospitalized patients: magnitude and predictability of interindividual differences. Clin Pharmacol Ther 1982; 32: 503-16
32. Zhou H-H, Koshakji RP, Silberstein DJ, et al. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989; 320: 565-70
33. Lew KH, Ludwig EA, Milad MA, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 402-14
34. Contin M, Riva R, Albani F. et al. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996; 30: 463-81
35. Triggs EJ, Charles BG, Contin M, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996; 51: 59-68
36. Levy G. The case for preclinical pharmacodynamics. In: Yacobi A, Shah VP, Skelly JP, et al., editors. Integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. New York: Plenum Press, 1993: 7-13